Title: Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management (CAG-00466N)

Decision: The Centers for Medicare & Medicaid Services (CMS) established a National Coverage Determination (NCD) to cover implantable pulmonary artery pressure sensors (IPAPS) for heart failure management under Coverage with Evidence Development (CED). Implantation of an IPAPS is covered for Medicare patients for the management of chronic heart failure (heart failure of at least 3 months duration) when furnished according to a Food and Drug Administration (FDA) market-authorized indication and within a CMS-approved CED study. Nothing in this NCD would prevent coverage of IPAPS for heart failure management through NCD 310.1 (Clinical Trial Policy) or through an Investigational Device Exemption (IDE) study.

What this means: Coverage of implantable pulmonary artery pressure sensors (IPAPS) for heart failure management was previously subject to Medicare Administrative Contractor (MAC) local coverage determinations, when applicable, or at the discretion of HealthPartners. IPAPS for the management of heart failure will now be covered for individuals who meet the criteria outlined in the Medicare NCD. Please refer to the final decision memo for all coverage criteria.

Effective: January 13, 2025

This announcement can be found at: <u>Implantable Pulmonary Artery</u>
<u>Pressure Sensors for Heart Failure Management</u>

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.